Table 3.

Risk for lung cancer.

Analysis time	Antibody	Subtype	Person-years	No. observed	No. expected	SIR (95% CI)	p-value
Overall risk	All	limited	26624	24	18.9	1.27 (0.81–1.89)	0.29
		diffuse	11062	6	6.6	0.91 (0.34–1.99)	0.99
	Cenp	limited	11857	8	9.6	0.83 (0.36–1.63)	0.75
		diffuse	754	0	0.6	0.00 (0.00–6.27)	0.99
	Topo	limited	4035	6	2.5	2.40 (0.88–5.23)	0.084
		diffuse	3134	2	1.7	1.19 (0.14–4.31)	0.99
	Pol III	limited	962	3	0.7	4.31 (0.89–12.61)	0.067
		diffuse	2509	2	1.6	1.28 (0.15–4.62)	0.93
	CTP-Negative	limited	4065	2	2.5	0.81 (0.10–2.91)	0.99
		diffuse	1709	0	0.9	0.00 (0.00–3.91)	0.78
± 3 years	All	limited	7935	5	3.9	1.27 (0.41–2.96)	0.72
		diffuse	5210	2	2.7	0.75 (0.09–2.73)	0.99
	Cenp	limited	3003	0	1.6	0.00 (0.00–2.28)	0.40
		diffuse	212	0	0.1	0.00 (0.00–35.12)	0.99
	Topo	limited	1353	2	0.6	3.42 (0.41–12.34)	0.23
		diffuse	1393	1	0.6	1.69 (0.04–9.41)	0.89
	Pol III	limited	305	2	0.2	10.43 (1.26–37.67)	0.032
		diffuse	1209	2	0.7	2.80 (0.34–10.11)	0.32
	CTP-Negative	limited	1335	0	0.5	0.00 (0.00–6.88)	0.99
		diffuse	808	0	0.4	0.00 (0.00–10.48)	0.99

^**Statistically significant p-value after adjustment for multiple (10) comparisons per analysis